In-depth reporting and analysis of the peptide supply chain.
The scramble to scale peptide production has ignited a high-stakes global investment race. At TIDES Europe, manufacturers will confront the technological and commercial challenges of turning that capacity into reliable supply.
READ FEATURE →
Billions are pouring into new peptide factories worldwide, creating major opportunities for upstream suppliers. But the scale of that opportunity will depend on how much raw-material demand actually reaches the open market.
READ FEATURE →
Highfine’s timetable narrows the expected trial-production window for a project planned to include 290 tonnes/year of protected amino acids and 2,500 tonnes/year of coupling reagents. Those volumes cannot yet be assigned to the first workshops entering trials.
READ FEATURE →
TideMetrix Take: Corden is assembling a global peptide manufacturing powerhouse. The AmbioPharm acquisition adds large-scale Chinese production, a second US peptide site and further capacity already under construction.
READ FEATURE →